Artiva Biotherapeutics (ARTV) Gains from Investment Securities (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Gains from Investment Securities for 3 consecutive years, with $291000.0 as the latest value for Q4 2025.
- On a quarterly basis, Gains from Investment Securities rose 19.75% to $291000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $442000.0, a 196.64% increase, with the full-year FY2025 number at $442000.0, up 196.64% from a year prior.
- Gains from Investment Securities was $291000.0 for Q4 2025 at Artiva Biotherapeutics, up from -$291000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $409000.0 in Q2 2025 to a low of -$291000.0 in Q3 2025.
- A 3-year average of $51500.0 and a median of $1000.0 in 2023 define the central range for Gains from Investment Securities.
- Biggest YoY gain for Gains from Investment Securities was 640.0% in 2024; the steepest drop was 454.84% in 2024.
- Artiva Biotherapeutics' Gains from Investment Securities stood at -$45000.0 in 2023, then soared by 640.0% to $243000.0 in 2024, then rose by 19.75% to $291000.0 in 2025.
- Per Business Quant, the three most recent readings for ARTV's Gains from Investment Securities are $291000.0 (Q4 2025), -$291000.0 (Q3 2025), and $409000.0 (Q2 2025).